

## · 指南与共识 ·

**编者按** 严重过敏反应是指机体在接触过敏原后突发的、严重的、可危及生命的全身性过敏反应,诊断不及时、救治不当可导致严重后果。《严重过敏反应急救指南》是在国家卫生健康委员会医疗管理服务指导中心的指导下,由多个相关学会和机构合作制订的循证指南。在该指南全文正式发布前,本刊先行刊出该指南关于严重过敏反应诊断、救治和救治后管理的 26 条推荐意见,以使临床尽快得到关于严重过敏反应急救的指导,同时征求对该指南的反馈意见。

## 《严重过敏反应急救指南》推荐意见

李晓桐<sup>1,2,3</sup> 翟所迪<sup>1,2</sup> 王强<sup>4</sup> 王育琴<sup>5</sup> 尹佳<sup>6</sup> 陈玉国<sup>7</sup> 陈荣昌<sup>8</sup> 张洪君<sup>9</sup> 杨克虎<sup>10</sup>  
李天佑<sup>11</sup> 郑亚安<sup>12</sup> 马青变<sup>12</sup> 刘芳<sup>1,2</sup> 崔畅<sup>1,2,3</sup> 郑航慈<sup>1,2,3</sup>

<sup>1</sup>北京大学第三医院药剂科 100191; <sup>2</sup>北京大学医学部药物评价中心 100191; <sup>3</sup>北京大学药学院药事管理与临床药学系 100191; <sup>4</sup>国家卫生健康委员会医疗管理服务指导中心,北京 100190; <sup>5</sup>首都医科大学宣武医院药学部,北京 100053; <sup>6</sup>中国医学科学院北京协和医院变态反应科 100005; <sup>7</sup>山东大学齐鲁医院急诊科,济南 250012; <sup>8</sup>广州医科大学附属第一医院呼吸内科 510120; <sup>9</sup>北京大学第三医院护理部 100191; <sup>10</sup>兰州大学循证医学中心 730000; <sup>11</sup>首都医科大学附属北京同仁医院麻醉科 100730; <sup>12</sup>北京大学第三医院急诊科 100191

通信作者:翟所迪,Email: zhaisuodi@163.com

DOI: 10.3760/cma.j.issn.1008-5734.2019.02.002

**【摘要】** 《严重过敏反应急救指南》的推荐意见围绕严重过敏反应的诊断、救治准备、救治措施和救治后管理回答了 15 个临床问题,共形成 26 条推荐意见。推荐意见中的证据质量分为高、中、低和极低 4 级,推荐强度分为强、弱 2 级。推荐意见的强度主要基于对利弊的权衡,不完全依赖于证据质量。临床严重过敏反应的急救可参照推荐意见实施。

**【关键词】** 指南; 过敏反应; 休克; 急救医学; 循证医学; 肾上腺素; 糖皮质激素类

**Recommendations in Guideline for Emergency Management of Anaphylaxis**

Li Xiaotong<sup>1,2,3</sup>, Zhai Suodi<sup>1,2</sup>, Wang Qiang<sup>4</sup>, Wang Yuqin<sup>5</sup>, Yin Jia<sup>6</sup>, Chen Yugu<sup>7</sup>, Chen Rongchang<sup>8</sup>, Zhang Hongjun<sup>9</sup>, Yang Kehu<sup>10</sup>, Li Tianzuo<sup>11</sup>, Zheng Ya'an<sup>12</sup>, Ma Qingbian<sup>12</sup>, Liu Fang<sup>1,2</sup>, Cui Chang<sup>1,2,3</sup>, Zheng Hangci<sup>1,2,3</sup>

<sup>1</sup>Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China; <sup>2</sup>Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China; <sup>3</sup>Department of Pharmacy Administration and Clinical Pharmacy, Peking University School of Pharmaceutical Sciences, Beijing 100191, China; <sup>4</sup>National Center for Medical Service Administration, National Health Commission of the People's Republic of China, Beijing 100190, China; <sup>5</sup>Department of Pharmacy, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; <sup>6</sup>Department of Allergy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100005, China; <sup>7</sup>Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan 250012, China; <sup>8</sup>Department of Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China; <sup>9</sup>Department of Nursing, Peking University Third Hospital, Beijing 100191, China; <sup>10</sup>Evidence-based Medicine Center, Lanzhou University, Lanzhou 730000, China; <sup>11</sup>Department of Anesthesiology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China; <sup>12</sup>Department of Emergency Medicine, Peking University Third Hospital, Beijing 100191, China

Corresponding author: Zhai Suodi, Email: zhaisuodi@163.com

**【Abstract】** The recommendations of *Guideline for Emergency Management of Anaphylaxis* answered 15 clinical questions about diagnosis, preparation for treatment, treatment measures, and post-treatment management of anaphylaxis and a total of 26 recommendations were formed. In the recommendations, the quality of evidence was divided into 4 levels: high, moderate, low, and very low. And the strength of recommendation was divided into 2 levels: strong and weak. The strength of recommendations was mainly determined by weighing the advantages and disadvantages, instead of relying on the quality of evidence. Emergency management of anaphylaxis in clinical practice could be carried out with reference to the recommendations of this guideline.

**【Key words】** Guideline; Anaphylaxis; Shock; Emergency medicine; Evidence-based medicine; Epinephrine; Glucocorticoids

严重过敏反应是指机体在接触过敏原后突发的、严重的、可危及生命的全身性过敏反应<sup>[1]</sup>。其主要临床特征为快速出现威胁生命的呼吸系统或/和循环系统问题,大部分情况下会出现皮肤黏膜系统症状<sup>[2]</sup>。严重过敏反应通常在患者接触过敏原后数分钟至数小时内发作<sup>[1]</sup>。部分患者(0.4%~23.3%)会发生双相反应,即患者初次发作的症状缓解后,在未接触过敏原的情况下严重过敏反应的症状再次发作<sup>[3-5]</sup>;双相反应的发作间隔时间范围为数分钟至数天<sup>[4]</sup>。还有小部分患者会发生迟发性严重过敏反应,即在接触过敏原后数小时至数天内发作<sup>[6-8]</sup>。

我国对严重过敏反应的认识尚存在不足,缺少统一的诊断标准和救治规范,临床救治措施有许多不合理之处<sup>[9-10]</sup>,亟需科学、合理的指导。因此,在国家卫生健康委员会医疗管理服务指导中心的指导下,由中国药理学学会药源性疾病专业委员会、中国医师协会变态反应医师分会、中华医学会变态反应学分会、中华医学会急诊医学分会、中华医学会呼吸病学分会、中华医学会麻醉医学分会、中国药学会医院药学专业委员会和中华护理学会联合发起《严重过敏反应急救指南》制订,由北京大学第三医院药剂科负责进行相关调研、制作循证证据并起草指南,兰州大学循证医学中心提供技术支持。根据美国医学科学院制定的临床实践指南定义<sup>[11]</sup>和 2014 年发布的《世界卫生组织指南制订手册》中关于指南的制订流程以及相关方法学标准<sup>[12]</sup>,指南的制订流程包括指南项目组筹建、指南注册与撰写计划书、临床问题和结局指标的收集与遴选、开题会确定临床问

题与结局指标排序、证据的制作与形成、推荐意见的起草、专家共识形成推荐意见、推荐意见的外审与修订、指南全文的撰写与发布、指南的传播与实施、指南的评价及更新等。

本指南采用推荐分级的评估、制定与评价标准(Grades of Recommendations Assessment, Development and Evaluation, GRADE)系统评价原始证据,将证据质量分为高(A)、中(B)、低(C)和极低(D)4级,将推荐强度分为强(1)、弱(2)2级(表 1)<sup>[13-14]</sup>。在使用指南研究与评价工具(Appraisal of Guidelines for Research and Evaluation, AGREE II)<sup>[15]</sup>评价其他指南<sup>[2-3, 16-32]</sup>的基础上,本指南项目组专家基于现有最佳证据与经验形成推荐意见;推荐意见的强度主要基于对利弊的权衡,不完全依赖于证据质量<sup>[13]</sup>。

完整的指南包括前言、制订方法与正文 3 部分,正文包括推荐意见、证据总结、推荐说明等内容。推荐意见部分由围绕严重过敏反应的诊断、救治准备、救治措施和救治后管理等方面的 26 条推荐意见组成。现先行发表该指南的 26 条推荐意见,全文及相关资料以后将在其他刊物上发表。

## 1 严重过敏反应的诊断

**临床问题 1** 诊断标准是什么?

**推荐意见** 严重过敏反应的诊断应采用表 2 列出的诊断标准,并注意患者可能出现其他非典型的症状。(1A,强推荐,高质量证据<sup>[33-34]</sup>)

**临床问题 2** 严重过敏反应如何分级?

**推荐意见** 严重过敏反应分级标准见表 3,以患者出现的最严重症状为准。(1D,强推荐,极低质量证据)

表 1 推荐分级的评估、制定与评价标准中关于证据质量等级与推荐强度的描述

Tab 1 Description about quality of evidence and strength of recommendations in Grades of Recommendations Assessment, Development and Evaluation

分级	具体描述	研究类型
<b>证据质量</b>		
高质量(A)	非常确信真实的效应值接近效应估计值	1. 设计优良的随机对照试验 2. 质量升高 2 级的观察性研究
中等质量(B)	对估计效应值有中等程度的信心:真实效应值可能与估计效应值相近,不排除大不相同的可能	1. 质量降低 1 级的随机对照试验 2. 质量升高 1 级的观察性研究
低质量(C)	对估计效应值的信任程度有限:真实效应值可能与估计效应值大不相同	1. 质量降低 2 级的随机对照试验 2. 观察性研究
极低质量(D)	对估计效应值几乎没有信心,真实效应值很可能与估计效应值大不相同	1. 质量降低 3 级的随机对照试验 2. 质量降低 1 级的观察性研究 3. 病例序列报告 4. 个案报道
<b>推荐强度</b>		
强(1)	遵从推荐意见利大于弊	
弱(2)	遵从推荐意见时利弊不确定或利弊相当(证据质量、意愿和价值观等方面可能存在较大不确定性)	

**表 2 严重过敏反应的诊断标准<sup>a</sup>**  
**Tab 2 Diagnostic criteria for anaphylaxis**

当症状满足以下 3 个标准的任意一个时,患者极可能发生了急性严重过敏反应	
1	疾病呈急性发作(几分钟至数小时内),有皮肤和/或黏膜系统症状,如皮疹,瘙痒或潮红,唇舌红肿和/或麻木等,及以下任一系统症状(不考虑过敏原接触史) A. 呼吸系统症状,如音哑、咳嗽、胸闷、气短、呼吸困难、喘鸣、支气管痉挛、发绀、呼气流量峰值下降、血氧不足等 B. 血压下降(见标准 3)或其相关的终末器官功能障碍,如麻木、肌张力减退、晕厥、大小便失禁等
2	患者接触可疑过敏原后几分钟至数小时内有下述 2 项及以上的症状快速发作 A. 皮肤黏膜组织症状,如各种皮疹,瘙痒或潮红,唇舌红肿和/或麻木等 B. 呼吸系统症状,如胸闷、气短、呼吸困难、喘鸣、支气管痉挛、发绀、呼气流量峰值下降、血氧不足等 C. 血压下降或终末器官功能受累,如肌张力减退、晕厥、大小便失禁等 D. 持续的胃肠系统症状,如腹痛、恶心、呕吐等
3	患者接触已知过敏原后几分钟至数小时内血压下降 A. 婴儿与儿童:收缩压低于相应年龄的正常值 [ <1 岁,收缩压 <70 mmHg; 1~10 岁,收缩压 <(70 mmHg + 2 × 年龄); 11~17 岁,收缩压 <90 mmHg] 或比基础值下降 >30% B. 成人:收缩压低于 90 mmHg 或比基础值下降 >30%

注 <sup>a</sup>: 基于美国国立变态反应和传染病研究所/食物过敏和过敏反应网络的诊断标准<sup>[1]</sup>,并参考我国医务工作者临床经验改编;1 mmHg = 0.133 kPa

**表 3 严重过敏反应的分级标准<sup>a</sup>**  
**Tab 3 Grading criteria for anaphylaxis**

分级	临床表现
I 级	只有皮肤黏膜系统症状和胃肠系统症状,血流动力学稳定,呼吸系统功能稳定 皮肤黏膜系统症状:皮疹,瘙痒或潮红,唇舌红肿和/或麻木等 胃肠系统症状:腹痛,恶心、呕吐等
II 级	出现明显呼吸系统症状或血压下降 呼吸系统症状:胸闷、气短、呼吸困难、喘鸣、支气管痉挛、发绀、呼气流量峰值下降、血氧不足等 血压下降:成人收缩压 80~90 mmHg 或比基础值下降 30%~40%; 婴儿与儿童: <1 岁,收缩压 <70 mmHg; 1~10 岁:收缩压 <(70 mmHg + 2 × 年龄); 11~17 岁:收缩压 <90 mmHg 或比基础值下降 30%~40%
III 级	出现以下任一症状:神志不清、嗜睡、意识丧失、严重的支气管痉挛和/或喉头水肿、发绀、重度血压下降(收缩压 <80 mmHg 或比基础值下降 >40%)、大小便失禁等
IV 级	发生心跳和/或呼吸骤停

注 <sup>a</sup>: 参考 Brown<sup>[35]</sup> 提出的标准;1 mmHg = 0.133 kPa

**2 严重过敏反应救治的准备**

**临床问题 3** 在医务工作者到来之前,患者/旁人应当采取何种措施?

**推荐意见** 患者发生疑似严重过敏反应后,患者/旁人应立即拨打急救电话或送往附近医院,并应当寻求在场或附近的医务工作者帮助。在医务工作者到来前,应尽可能迅速地使患者脱离过敏原,平卧;如果患者有呕吐,应保持患者头部偏向一侧并清除异物,以防患者误吸呕吐物导致窒息。(1D, 强推荐, 极低质量证据<sup>[36]</sup>)

**临床问题 4** 对院前和院内的急救设备有何要求?

**推荐意见** 院前和院内的急救设备中应当配备肾上腺素注射液,根据相关规定及资源的可及性进行其他配备。(1D, 强推荐, 极低质量证据<sup>[36-37]</sup>)

**3 严重过敏反应的救治措施**

**临床问题 5** 严重过敏反应救治过程中应当如何进行监护?

**推荐意见** 严重过敏反应救治过程中应对心脏、血压、呼吸、血氧饱和度实施密切监护。(1D, 强推荐, 极低质量证据)

**临床问题 6** 何种情况下需要建立人工气道,以及如何实施?

**推荐意见** 对于严重过敏反应患者,当发生气道水肿或支气管痉挛而导致严重呼吸困难时,应考虑气管插管或气管切开,紧急情况下对成人可行环甲膜穿刺。(1D, 强推荐, 极低质量证据)

**临床问题 7** 救治中应当如何正确使用肾上腺素?

**临床问题 7.1** 肾上腺素在严重过敏反应救治中的地位是什么?

**推荐意见** 对于 II 级及以上的严重过敏反应患者,肾上腺素是救治的首选药物。(1B, 强推荐, 中等质量证据<sup>[36-52]</sup>)

**临床问题 7.2** 肾上腺素的使用时机是什么?

**推荐意见** 肾上腺素应在患者被确诊为 II 级及以上的严重过敏反应后尽早使用。(1C, 强推荐, 低质量证据<sup>[38-39]</sup>)

**临床问题 7.3** 何种情况下,肾上腺素的给药方式应该采用肌内注射?

**推荐意见** 对于 II、III 级反应患者,应首选肌内注射肾上腺素;对于胃肠系统症状难以缓解的 I 级反应患者也可考虑肌内注射肾上腺素。(1C, 强推荐, 低质量证据<sup>[53-58]</sup>)

**临床问题 7.4** 肌内注射肾上腺素时应如何选择剂量和浓度?

**推荐意见** 剂量:肾上腺素按 0.01 mg/kg 体重给予,14 岁及以上患者单次最大剂量不超过 0.5 mg,14 岁以下患者单次最大剂量不超过 0.3 mg;浓度:1 mg/ml(1:1 000),等同于 1 ml:1 mg 规格的肾上腺素注射液浓度;5~15 min 后效果不理想者可重复给药。(1D,强推荐,极低质量证据<sup>[37]</sup>)

**临床问题 7.5** 肌内注射肾上腺素应该在什么部位?

**推荐意见** 肌内注射肾上腺素的部位为大腿中部外侧。(1C,强推荐,低质量证据<sup>[37,54]</sup>)

**临床问题 7.6** 何种情况下,肾上腺素应该采用静脉注射方式给药?

**推荐意见** 对于已发生或即将发生心跳和/或呼吸骤停的Ⅳ级反应患者,应静脉注射肾上腺素;对发生Ⅲ级反应且在 ICU 内/手术期间已建立静脉通路并得到监护的患者,可静脉注射肾上腺素。(1C,强推荐,低质量证据<sup>[57-58]</sup>)

**临床问题 7.7** 静脉注射肾上腺素应如何选择剂量和浓度?

**推荐意见** 静脉注射肾上腺素单次剂量,Ⅲ级反应:14 岁以上儿童及成人 0.1~0.2 mg,≤14 岁儿童 2~10 μg/kg;Ⅳ级:14 岁以上儿童及成人 0.5~1 mg,≤14 岁儿童 0.01~0.02 mg/kg;浓度:0.1 mg/ml(1:10 000),即将现有 1 ml:1 mg 规格的肾上腺素注射液稀释 10 倍;3~5 min 后效果不理想者可重复给药。(2D,弱推荐,极低质量证据)

**临床问题 7.8** 何种情况下,肾上腺素应该采用静脉滴注方式给药?

**推荐意见** 对于Ⅱ、Ⅲ级反应患者,静脉注射/肌内注射肾上腺素 2~3 次后,或 ICU 内/手术期间已建立静脉通路并得到监护后,可静脉滴注肾上腺素;对于Ⅳ级反应患者,症状改善但未完全缓解时,可考虑静脉滴注肾上腺素。(2C,弱推荐,低质量证据<sup>[36,57-58]</sup>)

**临床问题 7.9** 静脉滴注肾上腺素应如何选择剂量和浓度?

**推荐意见** 静脉滴注肾上腺素的剂量为 3~20 μg/(kg·h);浓度为 0.1~0.004 mg/ml(1:10 000~1:250 000),即将现有 1 ml:1 mg 规格的肾上腺素注射液稀释 10~250 倍。(2D,弱推荐,极低质量证据)

**临床问题 7.10** 何种情况下,推荐肾上腺素采用皮下注射方式给药?

**推荐意见** 不推荐在严重过敏反应的紧急救治中皮下注射肾上腺素。(1C,强推荐,低质量证

据<sup>[54-55,59-60]</sup>)

**临床问题 7.11** 使用肾上腺素的禁忌证是什么?

**推荐意见** 在危及生命的严重过敏反应紧急救治中,肾上腺素的使用没有绝对的禁忌证;但对于有心血管疾病史的患者和老年患者应权衡利弊谨慎使用。(2D,弱推荐,极低质量证据<sup>[37]</sup>)

**临床问题 7.12** 如何防范或处理使用肾上腺素所产生的不良反应?

**推荐意见** 为防范使用肾上腺素所产生的不良反应,应尽量避免不必要的静脉给药;静脉使用肾上腺素时应注意控制浓度,并进行持续心脏、血压、呼吸、血氧饱和度的监测。发生肾上腺素局部不良反应时,可使用酚妥拉明进行局部浸润注射。(1C,强推荐,低质量证据<sup>[61-62]</sup>)

**临床问题 8** H<sub>1</sub> 受体拮抗剂在严重过敏反应救治中的地位是什么?

**推荐意见** H<sub>1</sub> 受体拮抗剂可作为严重过敏反应救治的二线用药,主要用于缓解皮肤黏膜症状,不作为抢救药物使用。Ⅰ级反应患者可予口服,Ⅱ级反应及以上患者在给予肾上腺素抢救后可予口服或静脉滴注。(1D,强推荐,极低质量证据<sup>[42-45,48-52,63]</sup>)

**临床问题 9** 吸入 β<sub>2</sub> 受体激动剂在严重过敏反应救治中的地位是什么?

**推荐意见** 短效 β<sub>2</sub> 受体激动剂可作为严重过敏反应救治的二线用药,有支气管痉挛、呼吸困难、喘鸣的患者可吸入短效 β<sub>2</sub> 受体激动剂。(1D,强推荐,极低质量证据<sup>[42-43,45,47-52,63]</sup>)

**临床问题 10** 糖皮质激素在严重过敏反应救治中的地位是什么?

**推荐意见** 糖皮质激素可作为严重过敏反应救治的二线用药。口服或静脉注射糖皮质激素可能会降低发生双相反应或迟发相反应的风险;若患者出现持续的支气管痉挛,可考虑雾化吸入或静脉给予糖皮质激素。(1C,强推荐,低质量证据<sup>[36-37,42-52,63-69]</sup>)

**临床问题 11** 液体复苏在严重过敏反应救治中的地位是什么?

**推荐意见** 液体复苏可用于严重过敏反应伴循环系统不稳定的患者,液体用量一般为 20 ml/kg,根据患者情况调整剂量。(1D,强推荐,极低质量证据<sup>[36-37]</sup>)

#### 4 严重过敏反应救治后的管理

**临床问题 12** 救治成功后应当监护多长时间?

**推荐意见** 严重过敏反应患者经救治脱离危险后,应当在医院监护至少 12 h,监测患者的心脏、血压、呼吸、血氧饱和度和尿量。(1C,强推荐,低质量证据<sup>[70]</sup>)

**临床问题 13** 如何上报药源性严重过敏反应病例?

**推荐意见** 应上报所有药源性严重过敏反应病例, 上报内容包括可疑致敏原、发作症状描述(包括接触致敏原到发作的间隔时间)、抢救措施与患者转归, 具体参见《药品不良反应报告和监测管理办法》<sup>[71]</sup>。(1D, 强推荐, 极低质量证据)

**临床问题 14** 患者离院时医护人员应当如何进行患者教育?

**推荐意见** 患者离院时, 医护人员应对患者或患儿的监护人进行疾病定义、诊断标准、避免再次接触潜在过敏原、一线救治措施的宣教, 以使患者能够自我识别过敏反应并进行紧急处理。(1C, 强推荐, 低质量证据<sup>[72-73]</sup>)

**临床问题 15** 如何预防严重过敏反应的发生?

**推荐意见** 首选预防措施为避免接触过敏原。既往发生严重过敏反应者必须接触可疑过敏原时, 可考虑提前 6~12 h 应用糖皮质激素进行预防, 糖皮质激素可能降低严重过敏反应的发生率, 但不能绝对避免严重过敏反应的发生, 因而仍需在预防用药后密切监测, 做好救治准备。不推荐对无过敏史人群进行预防用药。(1C, 强推荐, 低质量证据<sup>[74-84]</sup>)

**指导委员会成员(按姓氏笔画为序)** 陈荣昌、陈玉国、李天佐、王强、王育琴、杨克虎、尹佳、翟所迪、张洪君

**指南专家组成员** 陈耀龙、董海龙、谷庆隆、郭代红、胡雪慧、解立新、李葆华、李玉珍、林桐榆、刘芳、刘志强、吕兰婷、马青变、梅全喜、邵洁、唐熠达、辛华雯、杨帆、杨辉、杨婉花、姚煦、于春水、詹思延、张国强、郑亚安

**指南外审组组长** 马青变、王明贵、郑亚安、朱珠

**指南制订工作组成员** 崔畅、邓述华、顾建青、黄超、黄雅群、李丽莎、李晓桐、刘鹏飞、吕园、门鹏、邵春雨、王宽、王赛、王小琴、鲜墨、熊亚娟、郑航慈、周鹏翔

**利益冲突** 所有作者均声明不存在利益冲突

**参考文献**

[1] Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis; summary report--second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium[J]. *Ann Emerg Med*, 2006, 47(4): 373-380. DOI: 10.1016/j.annemergmed.2006.01.018.

[2] Soar J, Pumphrey R, Cant A, et al. Emergency treatment of anaphylactic reactions--guidelines for healthcare providers[J]. *Resuscitation*, 2008, 77(2): 157-169. DOI: 10.1016/j.resuscitation.2008.02.001.

[3] Simons FE, Arduoso LR, Bilò MB, et al. World allergy organization guidelines for the assessment and management of anaphylaxis[J]. *World Allergy Organ J*, 2011, 4(2): 13-37. DOI: 10.1097/WOX.0b013e318211496c.

[4] Lee S, Belloio MF, Hess EP, et al. Time of onset and predictors of biphasic anaphylactic reactions: a systematic review and meta-analysis[J]. *J Allergy Clin Immunol Pract*, 2015, 3(3): 408-416. DOI: 10.1016/j.jaip.2014.12.010.

[5] Tole JW, Lieberman P. Biphasic anaphylaxis: review of incidence, clinical predictors, and observation recommendations[J]. *Immunol Allergy Clin North Am*, 2007, 27(2): 309-326. DOI: 10.1016/j.iacl.2007.03.011.

[6] Limb SL, Starke PR, Lee CE, et al. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma[J]. *J Allergy Clin Immunol*, 2007, 120(6): 1378-1381. DOI: 10.1016/j.jaci.2007.09.022.

[7] Vinuya R Z, Simon M R, Schwartz L B. Elevated serum tryptase levels in a patient with protracted anaphylaxis[J]. *Ann allergy*, 1994, 73(3): 232-234.

[8] Zisa G, Riccobono F, Calamari A M, et al. A case of protracted hypotension as unique symptom of a biphasic anaphylaxis to amoxicillin[J]. *Eur Ann Allergy Clin Immunol*, 2009, 41(2): 60.

[9] Jiang N, Yin J, Wen L, et al. Characteristics of anaphylaxis in 907 Chinese patients referred to a tertiary allergy center: a retrospective study of 1,952 episodes[J]. *Allergy Asthma Immunol Res*, 2016, 8(4): 353-361. DOI: 10.4168/aaair.2016.8.4.353.

[10] Wang T, Ma X, Xing Y, et al. Use of Epinephrine in patients with drug-induced anaphylaxis: an analysis of the Beijing Pharmacovigilance Database[J]. *Int Arch Allergy Immunol*, 2017, 173(1): 51-60. DOI: 10.1159/000475498.

[11] Graham R, Mancher M, Wolman DM, et al. Clinical practice guidelines we can trust[M]. Washington (DC): National Academies Press (US), 2011.

[12] WHO handbook for guideline development - 2nd edition[EB/OL]. (2014) [2018-06-30]. <http://apps.who.int/medicinedocs/en/m/abstract/Js22083en/>.

[13] Guyatt G H, Oxman A D, Kunz R, et al. Going from evidence to recommendations[J]. *BMJ*, 2008, 336(7652): 1049-1051. DOI: 10.1136/bmj.39493.646875.AE.

[14] Balshem H, Helfand M, Schünemann H J, et al. GRADE guidelines: 3. Rating the quality of evidence[J]. *J clin epidemiol*, 2011, 64(4): 401-406. DOI: doi: 10.1016/j.jclinepi.2010.07.015.

[15] Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care[J]. *J Clin Epidemiol*, 2010, 63(12): 1308-1311. DOI: 10.1016/j.jclinepi.2010.07.001.

[16] Muraro A, Roberts G, Clark A, et al. The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immunology[J]. *Allergy*, 2007, 62(8): 857-871. DOI: 10.1111/j.1398-9995.2007.01421.x.

[17] Muraro A, Roberts G, Worm M, et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology[J]. *Allergy*, 2014, 69(8): 1026-1045. DOI: 10.1111/all.12437.

[18] Kolawole H, Marshall SD, Crilly H, et al. Australian and New Zealand Anaesthetic Allergy Group/Australian and New Zealand College of Anaesthetists perioperative anaphylaxis management guidelines[J]. *Anaesth Intensive Care*, 2017, 45(2): 151-158. DOI: 10.1177/0310057X1704500204.

[19] The diagnosis and management of anaphylaxis: an updated practice parameter[J]. *J Allergy Clin Immunol*, 2005, 115(3 Suppl 2): S483-523. DOI: 10.1016/j.jaci.2005.01.010.

[20] Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter; 2010 update[J]. *J Allergy Clin Immunol*, 2010, 126(3): 477-480. DOI: 10.1016/j.jaci.2010.06.022.

[21] Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015[J]. *Ann Allergy Asthma Immunol*, 2015, 115(5): 341-384. DOI: 10.1016/j.ana.2015.07.019.

[22] Simons FE, Arduoso LR, Dimov V, et al. World Allergy Organization anaphylaxis guidelines: 2013 update of the evidence base[J]. *Int Arch Allergy Immunol*, 2013, 162(3): 193-204. DOI:

- 10.1159/000354543.
- [23] Simons FE, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines[J]. *World Allergy Organ J*, 2015, 8(1): 32. DOI: 10.1186/s40413-015-0080-1.
- [24] Tse Y, Rylance G. Emergency management of anaphylaxis in children and young people: new guidance from the Resuscitation Council (UK) [J]. *Arch Dis Child Educ Pract Ed*, 2009, 94(4): 97-101. DOI: 10.1136/adc.2007.120378.
- [25] Ring J, Beyer K, Biedermann T, et al. Guideline for acute therapy and management of anaphylaxis: S2 Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Association of German Allergologists (AeDA), the Society of Pediatric Allergy and Environmental Medicine (GPA), the German Academy of Allergology and Environmental Medicine (DAAU), the German Professional Association of Pediatricians (BVKJ), the Austrian Society for Allergology and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Anaesthesiology and Intensive Care Medicine (DGAI), the German Society of Pharmacology (DGP), the German Society for Psychosomatic Medicine (DGPM), the German Working Group of Anaphylaxis Training and Education (AGATE) and the patient organization German Allergy and Asthma Association (DAAB) [J]. *Allergo J Int*, 2014, 23(3): 96-112. DOI: 10.1007/s40629-014-0009-1.
- [26] Campbell RL, Li JT, Nicklas RA, et al. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter[J]. *Ann Allergy Asthma Immunol*, 2014, 113(6): 599-608. DOI: 10.1016/j.anai.2014.10.007.
- [27] Baumgart K, Brown S, Gold M, et al. ASCIA guidelines for prevention of food anaphylactic reactions in schools, preschools and child-care centres[J]. *J Paediatr Child Health*, 2004, 40(12): 669-671. DOI: 10.1111/j.1440-1754.2004.00509.x.
- [28] Vale S, Smith J, Said M, et al. ASCIA guidelines for prevention of anaphylaxis in schools, pre-schools and childcare: 2012 update [J]. *J Paediatr Child Health*, 2013, 49(5): 342-345. DOI: 10.1111/jpc.12166.
- [29] Vale S, Smith J, Said M, et al. ASCIA guidelines for prevention of anaphylaxis in schools, pre-schools and childcare: 2015 update [J]. *J Paediatr Child Health*, 2015, 51(10): 949-954. DOI: 10.1111/jpc.12962.
- [30] Harper NJ, Dixon T, Dugué P, et al. Suspected anaphylactic reactions associated with anaesthesia [J]. *Anaesthesia*, 2009, 64(2): 199-211. DOI: 10.1111/j.1365-2044.2008.05733.x.
- [31] Kroigaard M, Garvey LH, Gillberg L, et al. Scandinavian clinical practice guidelines on the diagnosis, management and follow-up of anaphylaxis during anaesthesia [J]. *Acta Anaesthesiol Scand*, 2007, 51(6): 655-670. DOI: 10.1111/j.1399-6576.2007.01313.x.
- [32] Chamberlain D. Emergency medical treatment of anaphylactic reactions. Project Team of the Resuscitation Council (UK) [J]. *J Accid Emerg Med*, 1999, 16(4): 243-247. DOI: 10.1007/s11104-011-0885-9.
- [33] Campbell RL, Hagan JB, Manivannan V, et al. Evaluation of national institute of allergy and infectious diseases/food allergy and anaphylaxis network criteria for the diagnosis of anaphylaxis in emergency department patients[J]. *J Allergy Clin Immunol*, 2012, 129(3): 748-752. DOI: 10.1016/j.jaci.2011.09.030.
- [34] Loprinzi BCE, Motosue MS, Li JT, et al. Prospective validation of the NIAID/FAAN criteria for emergency department diagnosis of anaphylaxis[J]. *J Allergy Clin Immunol Pract*, 2016, 4(6): 1220-1226. DOI: 10.1016/j.jaip.2016.06.003.
- [35] Brown SG. Clinical features and severity grading of anaphylaxis [J]. *J Allergy Clin Immunol*, 2004, 114(2): 371-376. DOI: 10.1016/j.jaci.2004.04.029.
- [36] Kemp AM, Kemp SF. Pharmacotherapy in refractory anaphylaxis: when intramuscular epinephrine fails [J]. *Curr Opin Allergy Clin Immunol*, 2014, 14(4): 371-378. DOI: 10.1097/ACI.0000000000000080.
- [37] Dhimi S, Panesar SS, Roberts G, et al. Management of anaphylaxis: a systematic review [J]. *Allergy*, 2014, 69(2): 168-175. DOI: 10.1111/all.12318.
- [38] Fleming JT, Clark S, Camargo CA, et al. Early treatment of food-induced anaphylaxis with epinephrine is associated with a lower risk of hospitalization [J]. *J Allergy Clin Immunol Pract*, 2015, 3(1): 57-62. DOI: 10.1016/j.jaip.2014.07.004.
- [39] Hochstadter E, Clarke A, De Schryver S, et al. Increasing visits for anaphylaxis and the benefits of early epinephrine administration: a 4-year study at a pediatric emergency department in Montreal, Canada [J]. *J Allergy Clin Immunol*, 2016, 137(6): 1888-1890. e4. DOI: 10.1016/j.jaci.2016.02.016.
- [40] Sheikh A, Shehata YA, Brown SG, et al. Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock [J]. *Cochrane Database Syst Rev*, 2008, (4): CD006312. DOI: 10.1002/14651858.CD006312.pub2.
- [41] Rubin T, Clayton J, Adams D, et al. Systematic review of outcome measures in trials of pediatric anaphylaxis treatment [J]. *BMC Pediatr*, 2014, 14: 158. DOI: 10.1186/1471-2431-14-158.
- [42] Alqurashi W, Stiell I, Chan K, et al. Epidemiology and clinical predictors of biphasic reactions in children with anaphylaxis [J]. *Ann Allergy Asthma Immunol*, 2015, 115(3): 217-223. e2. DOI: 10.1016/j.anai.2015.05.013.
- [43] Ellis AK, Day JH. Incidence and characteristics of biphasic anaphylaxis: a prospective evaluation of 103 patients [J]. *Ann Allergy Asthma Immunol*, 2007, 98(1): 64-69. DOI: 10.1016/S1081-1206(10)60861-7.
- [44] Kim TH, Yoon SH, Lee SY, et al. Biphasic and protracted anaphylaxis to iodinated contrast media [J]. *Eur Radiol*, 2018, 28(3): 1242-1252. DOI: 10.1007/s00330-017-5052-0.
- [45] Ko BS, Kim JY, Seo DW, et al. Should adrenaline be used in patients with hemodynamically stable anaphylaxis? Incident case control study nested within a retrospective cohort study [J]. *Sci Rep*, 2016, 6: 20168. DOI: 10.1038/srep20168.
- [46] Lee S, Bellolio MF, Hess EP, et al. Predictors of biphasic reactions in the emergency department for patients with anaphylaxis [J]. *J Allergy Clin Immunol Pract*, 2014, 2(3): 281-287. DOI: 10.1016/j.jaip.2014.01.012.
- [47] Lee S, Peterson A, Lohse CM, et al. Further evaluation of factors that may predict biphasic reactions in emergency department anaphylaxis patients [J]. *J Allergy Clin Immunol Pract*, 2017, 5(5): 1295-1301. DOI: 10.1016/j.jaip.2017.07.020.
- [48] Lertnawapan R, Maek-a-nantawat W. Anaphylaxis and biphasic phase in Thailand: 4-year observation [J]. *Allergol Int*, 2011, 60(3): 283-289. DOI: 10.2332/allergolint.10-OA-0256.
- [49] Mehr S, Liew WK, Tey D, et al. Clinical predictors for biphasic reactions in children presenting with anaphylaxis [J]. *Clin Exp Allergy*, 2009, 39(9): 1390-1396. DOI: 10.1111/j.1365-2222.2009.03276.x.
- [50] Rohacek M, Edenhofer H, Bircher A, et al. Biphasic anaphylactic reactions: occurrence and mortality [J]. *Allergy*, 2014, 69(6): 791-797. DOI: 10.1111/all.12404.
- [51] Smit DV, Cameron PA, Rainer TH. Anaphylaxis presentations to an emergency department in Hong Kong: incidence and predictors of biphasic reactions [J]. *J Emerg Med*, 2005, 28(4): 381-388. DOI: 10.1016/j.jemermed.2004.11.028.
- [52] Sricharoen P, Sittichanbuncha Y, Wibulpolprasert A, et al. What clinical factors are associated with biphasic anaphylaxis in Thai adult patients? [J]. *Asian Pac J Allergy Immunol*, 2015, 33(1): 8-13. DOI: 10.12932/AP0477.33.1.2015.

- [53] Pensrichon R. Comparison of systemic absorption of epinephrine delivered intranasally (5 mg) vs intramuscularly (0.3 mg) using liquid chromatography with tandem mass spectrophotometry (LC-MS/MS)[J]. *J Allergy Clin Immunol*, 2012, 129(2): AB184. DOI: 10.1016/j.jaci.2011.12.254.
- [54] Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection[J]. *J Allergy Clin Immunol*, 2001, 108(5): 871-873. DOI: 10.1067/mai.2001.119409.
- [55] Simons FE, Roberts JR, Gu X, et al. Epinephrine absorption in children with a history of anaphylaxis[J]. *J Allergy Clin Immunol*, 1998, 101(1 Pt 1): 33-37. DOI: 10.1016/S0091-6749(98)70190-3.
- [56] Srisawat C, Nakponetong K, Benjasupattananun P, et al. A preliminary study of intranasal epinephrine administration as a potential route for anaphylaxis treatment[J]. *Asian Pac J Allergy Immunol*, 2016, 34(1): 38-43.
- [57] Campbell RL, Bellolio MF, Knutson BD, et al. Epinephrine in anaphylaxis; higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine[J]. *J Allergy Clin Immunol Pract*, 2015, 3(1): 76-80. DOI: 10.1016/j.jaip.2014.06.007.
- [58] Kawano T, Scheuermeyer FX, Gibo K, et al. H1-antihistamines reduce progression to anaphylaxis among emergency department patients with allergic reactions[J]. *Acad Emerg Med*, 2017, 24(6): 733-741. DOI: 10.1111/acem.13147.
- [59] Mellem H, Lande K, Kjeldsen S E, et al. Faster and more reliable absorption of adrenaline by aerosol inhalation than by subcutaneous injection[J]. *Br J of Clin Pharmacol*, 2012, 31(6): 677-681.
- [60] Safdar B, Cone DC, Pham KT. Subcutaneous epinephrine in the prehospital setting[J]. *Prehosp Emerg Care*, 2001, 5(2): 200-207. DOI: 10.1080/10903120190940137.
- [61] Cardona V, Ferré-Ybarz L, Guilarte M, et al. Safety of adrenaline use in anaphylaxis: a multicentre register[J]. *Int Arch Allergy Immunol*, 2017, 173(3): 171-177. DOI: 10.1159/000477566.
- [62] Cluck DB, Odle B, Rikhye S. Therapeutic management of accidental epinephrine injection[J]. *J Pharm Technol*, 2013, 29(3): 123-129. DOI: 10.1177/875512251302900304.
- [63] Scranon SE, Gonzalez EG, Waibel KH. Incidence and characteristics of biphasic reactions after allergen immunotherapy[J]. *J Allergy Clin Immunol*, 2009, 123(2): 493-498. DOI: 10.1016/j.jaci.2008.10.026.
- [64] Michelson KA, Monuteaux MC, Neuman MI. Glucocorticoids and hospital length of stay for children with anaphylaxis: a retrospective study[J]. *J Pediatr*, 2015, 167(3): 719-724. e1-3. DOI: 10.1016/j.jpeds.2015.05.033.
- [65] Okubo Y, Michihata N, Morisaki N, et al. Effects of glucocorticoids on hospitalized children with anaphylaxis[J]. *Pediatr Emerg Care*, 2018. DOI: 10.1097/PEC.0000000000001544.
- [66] Grunau BE, Wiens MO, Rowe BH, et al. Emergency department corticosteroid use for allergy or anaphylaxis is not associated with decreased relapses[J]. *Ann Emerg Med*, 2015, 66(4): 381-389. DOI: 10.1016/j.annemergmed.2015.03.003.
- [67] Choo KJ, Simons E, Sheikh A. Glucocorticoids for the treatment of anaphylaxis: cochrane systematic review[J]. *Allergy*, 2010, 65(10): 1205-1211. DOI: 10.1111/j.1398-9995.2010.02424.x.
- [68] Choo KJ, Simons FE, Sheikh A. Glucocorticoids for the treatment of anaphylaxis[J]. *Evid Based Child Health*, 2013, 8(4): 1276-1294. DOI: 10.1002/ebch.1925.
- [69] Pourmand A, Robinson C, Syed W, et al. Biphasic anaphylaxis: a review of the literature and implications for emergency management[J]. *Am J Emerg Med*, 2018, 36(8): 1480-1485. DOI: 10.1016/j.ajem.2018.05.009.
- [70] Lee J, Rodio B, Lavelle J, et al. The impact and safety of an updated anaphylaxis clinical pathway in a busy pediatric emergency department[J]. *J Allergy Clin Immunol*, 2017, 139(2): AB222. DOI: 10.1016/j.jaci.2016.12.719.
- [71] 中华人民共和国卫生部. 药品不良反应报告和监测管理办法[EB/OL]. (2011-05-04) [2018-05-30]. <http://eng.sfda.gov.cn/WS01/CL1031/62621.html>. Ministry of Health of the People's Republic of China. Management measures for adverse drug reaction reporting and monitoring[EB/OL]. (2011-05-04) [2018-05-30]. <http://eng.sfda.gov.cn/WS01/CL1031/62621.html>.
- [72] Brockow K, Schallmayer S, Beyer K, et al. Effects of a structured educational intervention on knowledge and emergency management in patients at risk for anaphylaxis[J]. *Allergy*, 2015, 70(2): 227-235. DOI: 10.1111/all.12548.
- [73] Choo K, Sheikh A. Action plans for the long-term management of anaphylaxis; systematic review of effectiveness[J]. *Clin Exp Allergy*, 2007, 37(7): 1090-1094. DOI: 10.1111/j.1365-2222.2007.02711.x.
- [74] de Silva HA, Pathmeswaran A, Ranasingha CD, et al. Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double-blind, placebo-controlled trial[J]. *PLoS Med*, 2011, 8(5): e1000435. DOI: 10.1371/journal.pmed.1000435.
- [75] Premawardhena AP, de Silva CE, Fonseka MM, et al. Low dose subcutaneous adrenaline to prevent acute adverse reactions to antivenom serum in people bitten by snakes: randomised, placebo controlled trial[J]. *BMJ*, 1999, 318(7190): 1041-1043. DOI: 10.1136/bmj.318.7190.1041.
- [76] Fan HW, Marcopito LF, Cardoso JL, et al. Sequential randomised and double blind trial of promethazine prophylaxis against early anaphylactic reactions to antivenom for bothrops snake bites[J]. *BMJ*, 1999, 318(7196): 1451-1452. DOI: 10.1136/bmj.318.7196.1451.
- [77] Kawano T, Grunau BE, Gibo K, et al. L0066: H1-antihistamine administration is associated with a lower likelihood of progression to anaphylaxis among emergency department patients with allergic reactions[J]. *CJEM*, 2016, 18(S1): S53. DOI: 10.1017/cem.2016.103.
- [78] 陈辉, 王骏, 谢叶, 等. 预防使用地塞米松在降低碘对比剂不良反应中的应用价值[J]. *中国临床研究*, 2017, 30(12): 1665-1666. DOI: 10.13429/j.cnki.cjcr.2017.12.023.
- Chen H, Wang J, Xie Y, et al. Application value of preventive use of dexamethasone in reducing adverse reactions of iodine contrast agents[J]. *Chin J Clin Res*, 2017, 30(12): 1665-1666. DOI: 10.13429/j.cnki.cjcr.2017.12.023.
- [79] Tramèr MR, von EE, Loubeyre P, et al. Pharmacological prevention of serious anaphylactic reactions due to iodinated contrast media: systematic review[J]. *BMJ*, 2006, 333(7570): 675. DOI: 10.1136/bmj.38905.634132.AE.
- [80] Delaney A, Carter A, Fisher M. The prevention of anaphylactoid reactions to iodinated radiological contrast media: a systematic review[J]. *BMC Med Imaging*, 2006, 6: 2. DOI: 10.1186/1471-2342-6-2.
- [81] Habib AG. Effect of pre-medication on early adverse reactions following antivenom use in snakebite: a systematic review and meta-analysis[J]. *Drug Saf*, 2011, 34(10): 869-80. DOI: 10.2165/11592050-000000000-00000.
- [82] 蔡和平, 张铃铃, 王卓, 等. 两种含地塞米松的紫杉醇过敏反应预处理方案的 Meta 分析[J]. *中国临床药理学杂志*. 2012, 21(2): 90-95.
- Cai HP, Zang LL, Wang Z, et al. Meta-analysis of therapeutic effect of two regimens contain dexamethasone to prevent paclitaxel's hypersensitivity[J]. *Chin J Clin Pharm*, 2012, 21(2): 90-95.

(收稿日期:2019-02-20)

(本文编辑:蔡皓东)